Etiological Factors of Obesity-Associated Hyperandrogenemia in Peripubertal Girls (CRM002)

The purpose of this study is to learn if obese pre- and early pubertal girls with hyperandrogenemia (HA) are more insulin resistant (i.e., have lower insulin-stimulated glucose disposal) compared to obese peripubertal girls without HA; and that overnight mean luteinizing hormone (LH) concentration is also an independent predictor of free testosterone concentrations, especially in mid- to late pubertal girls.

Study Overview

• Status: Recruiting
• Conditions: Obesity; Polycystic Ovary Syndrome; Hyperandrogenemia

Detailed Description

A number of pathophysiological mechanisms underlie the polycystic ovary syndrome (PCOS). Neuroendocrine abnormalities play a significant role in most women with PCOS, and PCOS is associated with relative resistance of the gonadotropin releasing hormone (GnRH) pulse generator to negative feedback by progesterone and estradiol. This hypothalamic resistance to negative feedback appears to be a result of hyperandrogenemia (HA), and can also occur in adolescents with HA. We have hypothesized that peripubertal HA (which can represent a forerunner of adult PCOS) can promote the development of PCOS in part via induction of hypothalamic resistance to negative feedback. However, the cause of peripubertal HA remains largely unknown. Obesity is a well-recognized pathophysiological factor in the HA of adult PCOS; and recent data demonstrate that peripubertal obesity is associated with HA. However, the mechanisms underlying the relationship between peripubertal obesity and HA-and the marked variability of androgen levels observed among obese girls-are unknown. We have gathered preliminary data that suggests that obese pre- and early pubertal girls with high androgen levels also exhibit greater degrees of insulin resistance compared to obese girls with lower androgens.

The primary goal of this pilot project is to begin to establish the relationship between insulin resistance (as determined by insulin clamp studies) and free testosterone concentrations in obese peripubertal girls. Secondarily, the aim is to assess the contributions of elevated luteinizing hormone (determined by frequent blood sampling for LH) in obesity-associated HA across puberty.

Subjects will be admitted to the General Clinical Research Center at 1600 h after 4 hours of fasting. We will measure luteinizing hormone every 10 minutes from 1800 h to 0900 h; other hormones (e.g., testosterone) will be assessed as well. Measurements of insulin and glucose will occur before and after a standardized mixed meal (eaten at 1900 h) and while fasting the following morning. A standard hyperinsulinemic euglycemic clamp procedure will be performed from 0900-1100 h.

Characterization of the factors underlying peripubertal HA may permit prediction of which pre- and early pubertal girls will subsequently go on to develop symptoms of PCOS. Data generated by this project will prompt novel future studies to investigate the complex interactions among metabolic and classical endocrine pathways that lead to PCOS.

• Study Type: Observational
• Enrollment (Anticipated): 40

Contacts and Locations

• Study Contact: Name: Christopher McCartney, MD; Phone Number: 434-243-6911; Email: cm2hq@virginia.edu

Study Locations

• United States
  • Virginia
    • Charlottesville, Virginia, United States, 22908
      • Recruiting
      • University of Virginia
      • Principal Investigator: Christopher McCartney, MD

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 8 years to 16 years (Child)
• Accepts Healthy Volunteers: Yes
• Genders Eligible for Study: Female

• Sampling Method: Non-Probability Sample

Study Population

Generally healthy peripubertal girls ages 8 - 16 years with a BMI of > or = to 95th percentile will be recruited from the general population of the surrounding area.

Description

Inclusion Criteria:

• Peripubertal (Tanner stage 1 to 5) girl, age 8-16 years
• Obesity (BMI-for-age ≥ 95th percentile)
• Generally healthy (save for exogenous obesity)
• Ability and willingness of subject/parents to provide informed assent/consent

Exclusion Criteria:

• Age < 8 or > 16 y
• Greater than 4 y post-menarche
• Obesity associated with a diagnosed (genetic) syndrome (e.g., Prader-Willi syndrome, leptin deficiency), obesity related to medications (e.g., glucocorticoids), etc.
• Pregnancy or lactation
• Virilization
• Total testosterone > 150 ng/dl, which suggests the possibility of a virilizing neoplasm
• DHEAS greater than twice upper limit of age-appropriate normal range
• 17-OHP greater than 250 ng/dl, which suggests the possibility of congenital adrenal hyperplasia (if postmenarcheal, the 17-OHP will be collected during the follicular phase, or > 60 if oligomenorrheic) NOTE: If a 17-OHP > 250 ng/dl is confirmed on repeat testing, an ACTH stimulation test will be offered, with a post-ACTH 17-OHP < 1000 ng/dl being required for study participation
• History of premature adrenarche (i.e., appearance of pubic and/or axillary hair before age 8)
• Fasting glucose > 125 mg/dl or hemoglobin A1c > 7.0%
• Abnormal TSH or prolactin
• Evidence of Cushing's syndrome by history or physical exam (e.g., history of impaired growth, striae)
• Hematocrit < 36% or hemoglobin < 12 g/dl
• Significant and current cardiac or pulmonary dysfunction (e.g., known or suspected congestive heart failure; asthma requiring systemic intermittent corticosteroids; etc.)
• Abnormal liver enzymes, age-specific alkaline phosphatase, or a bilirubin > 1.5 times upper limit of normal
• Abnormal sodium, potassium, bicarbonate concentrations, or elevated creatinine concentration
• Weight less than 34 kg is an exclusion criterion (to ensure safe blood withdrawal)
• Subjects using restricted medication (see restrictions below) are excluded unless the subject's primary care provider approves stopping the medication

Study Plan

How is the study designed?

Number of groups / cohorts

1

Cohorts and Interventions

Group / Cohort
peripubertal obese girls; Peripubertal obese girls, aged 8 - 16 years, who are obese (BMI-for-age percentile greater or equal to 95)

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Morning free testosterone	0700 to 0900 hours
Insulin-stimulated glucose disposal	0900 to 1100 hours

Secondary Outcome Measures

Outcome Measure	Time Frame
Estimated 24-hour mean insulin concentration	24 hours
Luteinizing hormone pulse frequency	1800 to 0900 hours
Mean luteinizing hormone concentration	1800 to 0900 hours

Collaborators and Investigators

• Sponsor: University of Virginia
• Collaborators: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
• Investigators: Principal Investigator: Christopher McCartney, MD, University of Virginia

Publications and helpful links

General Publications

• Burt Solorzano CM, Knudsen KL, Anderson AD, Hutchens EG, Collins JS, Patrie JT, Marshall JC, McCartney CR. Insulin Resistance, Hyperinsulinemia, and LH: Relative Roles in Peripubertal Obesity-Associated Hyperandrogenemia. J Clin Endocrinol Metab. 2018 Jul 1;103(7):2571-2582. doi: 10.1210/jc.2018-00131.

Study record dates

Study Major Dates

• Study Start: March 1, 2008
• Primary Completion (Anticipated): May 1, 2023
• Study Completion (Anticipated): August 1, 2023

Study Registration Dates

• First Submitted: October 28, 2008
• First Submitted That Met QC Criteria: June 25, 2009
• First Posted (Estimate): June 26, 2009

Study Record Updates

• Last Update Posted (Actual): May 18, 2022
• Last Update Submitted That Met QC Criteria: May 16, 2022
• Last Verified: May 1, 2022

More Information

Terms related to this study

• Keywords: Obesity; Polycystic Ovary Syndrome
• Additional Relevant MeSH Terms: Neoplasms; Endocrine System Diseases; Ovarian Cysts; Cysts; Ovarian Diseases; Adnexal Diseases; Gonadal Disorders; Overnutrition; Nutrition Disorders; Overweight; Body Weight; Polycystic Ovary Syndrome; Obesity
• Other Study ID Numbers: 13552; P50HD028934 (U.S. NIH Grant/Contract)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: UNDECIDED
• IPD Plan Description: We do not have current plans to share IPD

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No